ERBB2 and breast carcinoma: MIG-6 down-regulation in non-small cell lung cancer (NSCLC) is associated with increased EGFR signaling and poorly differentiated cancer [21], while loss of its expression in ErbB2-amplified breast carcinoma renders the cancer cells more resistant to Herceptin, the neutralizing antibody against ErbB2 [16].